AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (Currently amended): A method of treating a mammal suffering from or being susceptible to cancer, the method comprising administering to the mammal a therapeutically effective amount Use of a compound of the general formula (I)

$$\begin{array}{c|c}
X^{1} \\
R^{3} & & \\
X^{3} & & \\
X^{2} & & \\
X^{2} & & \\
X^{1} & & \\
X^{2} & & \\
X^{2} & & \\
X^{1} & & \\
X^{2} & & \\
X^{2} & & \\
X^{1} & & \\
X^{2} & & \\
X^{2} & & \\
X^{2} & & \\
X^{1} & & \\
X^{2} & & \\
X^{2} & & \\
X^{3} & & \\
X^{4} & & \\
X^{2} & & \\
X^{2} & & \\
X^{3} & & \\
X^{4} & & \\
X^{2} & & \\
X^{2} & & \\
X^{3} & & \\
X^{4} & & \\
X^{5} & & \\$$

wherein

 V^1 , V^2 , V^3 , and V^4 independently are selected from a carbon atom, a non-quaternary nitrogen atom, an oxygen atom, and a sulfur atom, and where V^4 further may be selected from a bond, so that $-V^1$ - V^2 - V^3 - V^4 - together with the atoms to which V^1 and V^4 are attached form an aromatic or heteroaromatic ring;

R¹, R², R³, and R⁴, when attached to a carbon atom, independently are selected from hydrogen, optionally substituted C₁₋₆-alkyl, optionally substituted C₂₋₆-alkenyl, hydroxy, optionally substituted C₁₋₆-alkoxy, optionally substituted C₂₋₆-alkenyloxy, carboxy, optionally substituted C₁₋₆alkoxycarbonyl, optionally substituted C_{1-6} -alkylcarbonyl, optionally substituted alkylcarbonyloxy, formyl, amino, mono- and di(C1-6-alkyl)amino, carbamoyl, mono- and di(C1-6alkyl)aminocarbonyl, C_{1-6} -alkylcarbonylamino, C_{1-6} -alkylsulphonylamino, cyano, carbamido, mono- and $di(C_{1-6}$ -alkyl)aminocarbonylamino, C_{1-6} -alkanoyloxy, C_{1-6} -alkylsulphonyl, C_{1-6} alkylsulphinyl, aminosulfonyl, mono- and di(C₁₋₆-alkyl)aminosulfonyl, nitro, optionally substituted C_{1-6} -alkylthio, aryl, aryloxy, arylcarbonyl, arylamino, heterocyclyl, heterocyclyloxy, heterocyclylamino, heterocyclylcarbonyl, heteroaryl, heteroaryloxy, heteroarylamino,

heteroarylcarbonyl, and halogen, where any C_{1-6} -alkyl as an amino substituent is optionally substituted with hydroxy, C_{1-6} -alkoxy, amino, mono- and di(C_{1-6} -alkyl)amino, carboxy, C_{1-6} -alkyl-carbonylamino, C_{1-6} -alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted;

R¹, R², R³, and R⁴, when attached to a nitrogen atom, independently are selected from hydrogen, optionally substituted C₁₋₆-alkyl, hydroxy, optionally substituted C₁₋₆-alkoxy, optionally substituted C_{1-6} -alkoxycarbonyl, optionally substituted C_{1-6} -alkylcarbonyl, formyl, mono- and di(C_{1-6} -alkyl)amino, C₁₋₆-alkylcarbonylamino, monoand $di(C_{1-6}$ -alkyl)amino, C_{1-6} aminocarbonyl, alkylsulphonyl, C₁₋₆-alkylsulphinyl, aryl, aryloxy, arylcarbonyl, arylamino, heterocyclyl, heterocyclyloxy, heterocyclylcarbonyl, heterocyclylamino, heteroaryl, heteroaryloxy, heteroarylcarbonyl, and heteroarylamino; where any C₁₋₆-alkyl as an amino substituent is optionally substituted with hydroxy, C₁₋₆-alkoxy, amino, mono- and di(C₁₋₆-alkyl)amino, carboxy, C₁₋₆-alkylcarbonylamino, C₁₋₆-alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted;

or R¹ and R² together with the carbon atoms to which they are attached form a ring, e.g. an aromatic ring, a carbocyclic ring, a heterocyclic ring or a heterocyclic ring, in particular an aromatic ring, a heterocyclic ring or a heterocyclic ring;

 X^1 and X^2 are independently selected from halogen, hydroxy, optionally substituted C_{1-6} -alkoxy, optionally substituted C_{1-6} -alkylcarbonyloxy, amino, mono- and di(C_{1-6} -alkyl)amino, C_{1-6} -alkylcarbonylamino, mono- and di(C_{1-6} -alkyl)aminocarbonylamino, C_{1-6} -alkylcarbonylamino, carboxy, mercapto, optionally substituted C_{1-6} -alkylthio, C_{1-6} -alkylsulfonyl, mono- and di(C_{1-6} -alkyl)aminosulfonyl, aryloxy, arylamino, heterocyclyloxy, heterocyclylamino, heteroaryloxy and heteroarylamino, where any C_{1-6} -alkyl as an amino or sulphur substituent is optionally substituted with hydroxy, C_{1-6} -alkoxy, amino, mono- and di(C_{1-6} -alkyl)amino, carboxy, C_{1-6} -alkylcarbonylamino, C_{1-6} -alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted;

 $>Y(=Q)_n$ is selected from >C=O, >C=S, >S=O and $>S(=O)_2$; and

 R^N is selected from the group consisting of hydrogen, optionally substituted C_{1-6} -alkyl, hydroxy, optionally substituted C_{1-6} -alkoxy, optionally substituted C_{1-6} -alkoxy, optionally substituted

 C_{1-6} -alkylcarbonyl, formyl, $di(C_{1-6}$ -alkyl)aminocarbonyl, monoand C_{1.6}alkylcarbonylamino, mono- and di(C_{1-6} -alkyl)amino, C_{1-6} -alkylsulphonyl, and C_{1-6} -alkylsulphinyl; where any C₁₋₆-alkyl as an amino substituent is optionally substituted with hydroxy, C₁₋₆-alkoxy, amino, mono- and di(C_{1-6} -alkyl)amino, carboxy, C_{1-6} -alkylcarbonylamino, C_{1-6} -alkylaminocarbonyl, or halogen(s); and

5

pharmaceutically acceptable salts and prodrugs thereof;

for the preparation of a medicament for the treatment of cancer in a mammal.

Claim 2 (Currently amended): The method use-according to claim 1, wherein R¹, R², R³ and R⁴ are not all hydrogen.

Claim 3 (Currently amended): The method use according to any one of the preceding claims claim 1, wherein the ring is selected from a benzene ring and a pyridine ring where the nitrogen atom represents V³.

Claim 4 (Currently amended): The method use according to any one of the preceding claimsclaim 1, wherein R^1 is selected from hydrogen, halogen, C_{1-6} -alkyl, trifluoromethyl and C_{1-6} -alkoxy, when V¹ is a carbon atom.

Claim 5 (Currently amended): The method use according to any one of the preceding claims claim 1, wherein R² is selected from hydrogen, halogen, optionally substituted aryl, optionally substituted aryloxy, and optionally substituted heteroaryl, when V² is a carbon atom.

Claim 6 (Currently amended): The method use according to any one of the preceding claims laim 1, wherein R³ is selected from hydrogen, optionally substituted C₁₋₆-alkoxy, halogen, cyano, optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, amino, C₁₋₆-alkylcarbonylamino, C_{1-6} -alkylsulphonylamino, and mono- and di(C_{1-6} -alkyl)aminosulfonyl, when V^3 is a carbon atom.

Docket No.: 20517/0205421-US0

Claim 7 (Currently amended): The method use according to any one of the preceding claims laim 1, wherein R⁴ is hydrogen, when V⁴ is a carbon atom.

Claim 8 (Currently amended): The method use-according to any one of the preceding claims claim 1, wherein X¹ and X² independently are selected from hydroxy, OAc, NH₂, NMe₂, NHAc, NHSO₂Me and NHCONMe₂.

Claim 9 - 10 (Canceled)

Claim 11 (Currently amended): The method use according to any one of the preceding claimsclaim $\underline{1}$, wherein V^1 , V^2 , V^3 , V^4 all are a carbon atom, $Y(=Q)_n$ is C=0, and R^N is hydrogen.

Claim 12 - 20 (Canceled)

Claim 21 (Currently amended): The method use according to any one of the claims claim 11-and 20, wherein R¹ is selected from fluoro, chloro, bromo, C₁₋₄-alkyl, trifluoromethyl, C₁₋₄-alkoxy, and dimethylaminocarbonyl.

Claim 22 (Canceled):

Claim 23 (Currently amended): The method use-according to any one of the claims claim 11 and 12, wherein R¹ is selected from halogen, C₁₋₄-alkyl, trifluoromethyl, C₁₋₄-alkoxy, and dimethylaminocarbonyl, R² is selected from hydrogen and halogen, and R³ is selected from hydrogen, halogen, C₁₋₄-alkyl, and amino; where R² and R³ are not both hydrogen.

Claim 24 (Currently amended): A method of treating a mammal suffering from or being susceptible to cancer, the method comprising administering to the mammal a therapeutically effective amount Use of a 3,3-diphenyl-1,3-dihydro-indol-2-one type compound of the formula (IIa)

$$R^3$$
 Z X^1 X^2 X^2 X^2 X^2 X^3 X^4 X^4 X^4 X^2 X^2 X^3 X^4 X^4

wherein

R¹ is selected from hydrogen, halogen, C₁₋₆-alkyl, trifluoromethyl and C₁₋₆-alkoxy;

7

R² is selected from hydrogen, halogen, optionally substituted aryl, optionally substituted aryloxy, and optionally substituted heteroaryl;

 R^3 is selected from hydrogen, optionally substituted $C_{1\text{--}6}$ -alkoxy, halogen, cyano, and optionally substituted aryl, optionally substituted aryloxy, optionally substituted heteroaryl, amino, C₁₋₆-alkylcarbonylamino, C₁₋₆-alkylsulphonylamino, and mono- and di(C₁₋₆-alkyl)aminosulfonyl;

Z is CH or N; and

X¹ and X² are independently selected from halogen, OR⁶, OCOR⁵, N(R⁶)₂, NHCOR⁵, NHSO₂R⁵, and NHCON(R^6)₂, wherein R^5 is selected from C_{1-6} -alkyl, optionally substituted aryl and optionally substituted heteroaryl, and each R⁶ independently is selected from hydrogen, C₁₋₆-alkyl, optionally substituted aryl and optionally substituted heteroaryl; and

pharmaceutically acceptable salts and prodrugs thereof;

for the preparation of a medicament for the treatment of cancer in a mammal.

Claim 25 (Currently amended): A method of treating a mammal suffering from or being susceptible to cancer, the method comprising administering to the mammal a therapeutically effective amount Use of a 3,3-diphenyl-1,3-dihydro-indol-2-one type compound of the formula (IIb)

$$\begin{array}{c|c}
X^1 \\
R^3 \\
Z \\
R^1 \\
H
\end{array}$$
(IIb)

wherein

R¹, R², and R³, when attached to a carbon atom, independently are selected from hydrogen, optionally substituted C₁₋₆-alkyl, optionally substituted C₂₋₆-alkenyl, hydroxy, optionally substituted C₁₋₆-alkoxy, optionally substituted C₂₋₆-alkenyloxy, carboxy, optionally substituted C₁₋₆alkoxycarbonyl, optionally substituted C_{1-6} -alkylcarbonyl, optionally substituted C_{1-6} alkylcarbonyloxy, formyl, amino, mono- and di(C1-6-alkyl)amino, carbamoyl, mono- and di(C1-6alkyl)aminocarbonyl, C₁₋₆-alkylcarbonylamino, C₁₋₆-alkylsulphonylamino, cyano, carbamido, mono- and $di(C_{1-6}$ -alkyl)aminocarbonylamino, C_{1-6} -alkanoyloxy, C_{1-6} -alkylsulphonyl, C_{1-6} alkylsulphinyl, aminosulfonyl, mono- and di(C₁₋₆-alkyl)aminosulfonyl, nitro, optionally substituted C₁₋₆-alkylthio, and halogen, where any C₁₋₆-alkyl as an amino substituent is optionally substituted with hydroxy, C₁₋₆-alkoxy, amino, mono- and di(C₁₋₆-alkyl)amino, carboxy, C₁₋₆-alkylcarbonylamino, C₁₋₆-alkylaminocarbonyl, or halogen(s); and

R¹, R², and R³, when attached to a nitrogen atom, independently are selected from hydrogen, optionally substituted C₁₋₆-alkyl, hydroxy, optionally substituted C₁₋₆-alkoxy, optionally substituted C₁₋₆-alkoxycarbonyl, optionally substituted C₁₋₆-alkylcarbonyl, formyl, mono- and di(C₁₋₆-alkyl)aminocarbonyl, amino, C_{1-6} -alkylcarbonylamino, mono- and di(C_{1-6} -alkyl)amino, C_{1-6} alkylsulphonyl, and C_{1-6} -alkylsulphinyl; where any C_{1-6} -alkyl as an amino substituent is optionally substituted with hydroxy, C₁₋₆-alkoxy, amino, mono- and di(C₁₋₆-alkyl)amino, carboxy, C₁₋₆-alkylcarbonylamino, C₁₋₆-alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted;

or wherein R¹ and R² together with the carbon and/or nitrogen atoms to which they are attached form a heterocyclic ring, a heteroaromatic ring, an aromatic ring or a carbocyclic ring;

Z is CH or N; and

X¹ and X² are independently selected from halogen, OR⁶, OCOR⁵, N(R⁶)₂, NHCOR⁵, NHSO₂R⁵, and NHCON(R⁶)₂, wherein R⁵ is selected from C₁₋₆-alkyl, optionally substituted aryl and optionally substituted heteroaryl, and each R⁶ independently is selected from hydrogen, C₁₋₆-alkyl, optionally substituted aryl and optionally substituted heteroaryl; and

pharmaceutically acceptable salts and prodrugs thereof;

for the preparation of a medicament for the treatment of cancer in a mammal.

Claim 26 (Currently amended): A method of treating a mammal suffering from or being susceptible to cancer, the method comprising administering to the mammal a therapeutically effective amount Use-of a 3,3-diphenyl-1,3-dihydro-indol-2-one type compound of the formula (IIc)

Docket No.: 20517/0205421-US0

$$R^3$$
 Z X^1 X^2 X^2 X^2 X^2 X^2 X^2 X^3 X^4 X^4 X^2 X^2 X^3 X^4 X^4

wherein

 R^1 is selected from hydrogen, halogen, $C_{1\text{-}6}$ -alkyl, trifluoromethyl and $C_{1\text{-}6}$ -alkoxy;

 R^2 is selected from hydrogen, halogen, optionally substituted aryl, optionally substituted aryloxy, and optionally substituted heteroaryl;

 R^3 is selected from hydrogen, optionally substituted $C_{1\text{-}6}$ -alkoxy, halogen, cyano, and optionally substituted aryl, optionally substituted heteroaryl, amino, $C_{1\text{-}6}$ -alkyl-carbonylamino, $C_{1\text{-}6}$ -alkylsulphonylamino, and mono- and di($C_{1\text{-}6}$ -alkyl)aminosulfonyl;

Z is CH or N; and

one of X^1 and X^2 is selected from halogen, OR^6 , $OCOR^5$, $N(R^6)_2$, $NHCOR^5$, $NHSO_2R^5$, and $NHCON(R^6)_2$, wherein R^5 is selected from C_{1-6} -alkyl, optionally substituted aryl and optionally substituted heteroaryl, and each R^6 independently is selected from hydrogen, C_{1-6} -alkyl, optionally substituted aryl and optionally substituted heteroaryl; and the other of X^1 and X^2 is selected from optionally substituted C_{1-6} -alkyl, optionally substituted C_{2-6} -alkenyl, carboxy, optionally substituted C_{1-6} -alkoxycarbonyl, optionally substituted C_{1-6} -alkylcarbonyl, formyl, carbamoyl, mono- and $di(C_{1-6}$ -alkyl)aminocarbonyl, cyano, aryl, arylcarbonyl, heterocyclyl, heterocyclylcarbonyl, heteroaryl, heteroarylcarbonyl, where any C_{1-6} -alkyl as an amino substituent is optionally substituted with hydroxy, C_{1-6} -alkoxy, amino, mono- and $di(C_{1-6}$ -alkyl)amino, carboxy, C_{1-6} -alkyl-carbonylamino, C_{1-6} -alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted; and

pharmaceutically acceptable salts and prodrugs thereof (as defined further above); for the preparation of a medicament for the treatment of cancer in a mammal.

Claim 27 (Currently amended): A method of treating a mammal suffering from or being susceptible to cancer, the method comprising administering to the mammal a therapeutically effective amount Use of a 3,3-diphenyl-1,3-dihydro-indol-2-one type compound of the formula (IId)

Docket No.: 20517/0205421-US0

$$R^3$$
 Z X^1 X^2 X^2 X^2 X^2 X^3 X^4 X^4 X^4 X^2 X^2 X^2 X^3 X^4 X^4

wherein

 R^1 , R^2 , and R^3 , when attached to a carbon atom, independently are selected from hydrogen, optionally substituted C_{1-6} -alkyl, optionally substituted C_{2-6} -alkenyl, hydroxy, optionally substituted C_{1-6} -alkoxy, optionally substituted C_{1-6} -alkenyloxy, carboxy, optionally substituted C_{1-6} -alkoxycarbonyl, optionally substituted C_{1-6} -alkylcarbonyl, optionally substituted C_{1-6} -alkylcarbonyl, optionally substituted C_{1-6} -alkylcarbonyloxy, formyl, amino, mono- and di(C_{1-6} -alkylsulphonylamino, carbamoyl, mono- and di(C_{1-6} -alkylsulphonylamino, cyano, carbamido, mono- and di(C_{1-6} -alkyl)aminosulfonyl, nitro, optionally substituted C_{1-6} -alkylsulphinyl, aminosulfonyl, mono- and di(C_{1-6} -alkyl)aminosulfonyl, nitro, optionally substituted C_{1-6} -alkylthio, and halogen, where any C_{1-6} -alkyl as an amino substituent is optionally substituted with hydroxy, C_{1-6} -alkoxy, amino, mono- and di(C_{1-6} -alkyl)amino, carboxy, C_{1-6} -alkylcarbonylamino, C_{1-6} -alkylaminocarbonyl, or halogen(s); and

 R^1 , R^2 , and R^3 , when attached to a nitrogen atom, independently are selected from hydrogen, optionally substituted C_{1-6} -alkyl, hydroxy, optionally substituted C_{1-6} -alkoxy, optionally substituted C_{1-6} -alkoxycarbonyl, optionally substituted C_{1-6} -alkylcarbonyl, formyl, mono- and di(C_{1-6} -alkyl)-aminocarbonyl, amino, C_{1-6} -alkylcarbonylamino, mono- and di(C_{1-6} -alkyl)amino, C_{1-6} -alkylsulphonyl, and C_{1-6} -alkylsulphinyl; where any C_{1-6} -alkyl as an amino substituent is optionally substituted with hydroxy, C_{1-6} -alkoxy, amino, mono- and di(C_{1-6} -alkyl)amino, carboxy, C_{1-6} -alkyl-carbonylamino, C_{1-6} -alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted;

or wherein R¹ and R² together with the carbon and/or nitrogen atoms to which they are attached form a heterocyclic ring, a heteroaromatic ring, an aromatic ring or a carbocyclic ring;

Docket No.: 20517/0205421-US0

Z is CH or N; and

one of X^1 and X^2 is selected from halogen, OR^6 , $OCOR^5$, $N(R^6)_2$, $NHCOR^5$, $NHSO_2R^5$, and $NHCON(R^6)_2$, wherein R^5 is selected from C_{1-6} -alkyl, optionally substituted aryl and optionally substituted heteroaryl, and each R^6 independently is selected from hydrogen, C_{1-6} -alkyl, optionally substituted aryl and optionally substituted heteroaryl; and the other of X^1 and X^2 is selected from optionally substituted C_{1-6} -alkyl, optionally substituted C_{1-6} -alkoxycarbonyl, optionally substituted C_{1-6} -alkylcarbonyl, formyl, carbamoyl, mono- and $di(C_{1-6}$ -alkyl)aminocarbonyl, cyano, aryl, arylcarbonyl, heterocyclyl, heterocyclylcarbonyl, heteroaryl, heteroarylcarbonyl, where any C_{1-6} -alkyl as an amino substituent is optionally substituted with hydroxy, C_{1-6} -alkoxy, amino, mono- and $di(C_{1-6}$ -alkyl)amino, carboxy, C_{1-6} -alkyl-carbonylamino, C_{1-6} -alkylaminocarbonyl, or halogen(s), and wherein any aryl, heterocyclyl and heteroaryl may be optionally substituted; and

pharmaceutically acceptable salts and prodrugs thereof;

for the preparation of a medicament for the treatment of cancer in a mammal.

Claim 28 (Currently amended): The <u>method use according to any one of the preceding claims claims</u> 1, wherein the compound is selected from Items 1 to 225 listed <u>below:herein.</u>

- 1 5-Amino-6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one
- 2 5-Chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one
- 3 5-Fluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 4 3,3-Bis-(4-hydroxy-phenyl)-5-nitro-1,3-dihydro-indol-2-one
- 5 3.3-Bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one
- 6 6-Bromo-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one
- 7 6-Bromo-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one
- 8 6-Bromo-3,3-bis-(4-hydroxy-phenyl)-5,7-dimethyl-1,3-dihydro-indol-2-one
- 9 6-Bromo-3,3-bis-(4-hydroxy-phenyl)-7-methyl-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile
- 10 6-Bromo-3,3-bis-(4-hydroxy-phenyl)-5-methoxy-7-methyl-1,3-dihydro-indol-2-one

6-Bromo-3,3-bis-(4-hydroxy-phenyl)-7-methoxy-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one;

- 12 6-Bromo-7-ethyl-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one
- 6-Bromo-7-ethyl-3,3-bis-(4-hydroxy-phenyl)-5-methyl-1,3-dihydro-indol-2-one
- 6-Bromo-5-ethyl-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one
- 6-Bromo-7-ethyl-3,3-bis-(4-hydroxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile
- 6-Bromo-7-ethyl-3,3-bis-(4-hydroxy-phenyl)-5-methoxy-1,3-dihydro-indol-2-one
- 17 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one
- 18 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one
- 19 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-5,7-dimethyl-1,3-dihydro-indol-2-one
- 20 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile
- 21 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-5-methoxy-7-methyl-1,3-dihydro-indol-2-one
- 22 <u>6-Chloro-3,3-bis-(4-hydroxy-phenyl)-7-methoxy-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one</u>
- 23 6-Chloro-7-ethyl-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one
- 24 6-Chloro-7-ethyl-3,3-bis-(4-hydroxy-phenyl)-5-methyl-1,3-dihydro-indol-2-one
- 25 6-Chloro-5-ethyl-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one
- 26 6-Chloro-7-ethyl-3,3-bis-(4-hydroxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile
- 27 6-Chloro-7-ethyl-3,3-bis-(4-hydroxy-phenyl)-5-methoxy-1,3-dihydro-indol-2-one
- 28 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-5-methyl-7-methoxy-1,3-dihydro-indol-2-one;
- 29 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-7-methoxy-2-oxo-2,3-dihydro-1H-indole-5-carbonitrile;
- 30 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-7-methoxy-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one;
- 31 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-7-methoxy-5-methyl-1,3-dihydro-indol-2-one;
- 32 6-Chloro-5-ethyl-3,3-bis-(4-hydroxy-phenyl)-7-methoxy-1,3-dihydro-indol-2-one;
- 33 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-5,7-dimethoxy-1,3-dihydro-indol-2-one;
- 34 N-{4-[3-(4-Acetylamino-phenyl)-5-chloro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl}-acetamide;
- 35 N-{4-[5-Chloro-3-(4-methanesulfonylamino-phenyl)-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl}-methanesulfonamide
- 36 N-{4-[3-(4-Acetylamino-phenyl)-6-chloro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl}-acetamide;

- 37 N-{4-[6-Chloro-3-(4-methanesulfonylamino-phenyl)-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-vl]-phenyl}-methanesulfonamide;
- 38 N-{4-[3-(4-Acetylamino-phenyl)-5-chloro-7-methoxy-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl}-acetamide;
- 39 N-{4-[5-Chloro-3-(4-methanesulfonylamino-phenyl)-7-methoxy-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl}-methanesulfonamide;
- 40 N-{4-[3-(4-Acetylamino-phenyl)-6-chloro-7-methoxy-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl}-acetamide; and
- 41 N-{4-[6-Chloro-3-(4-methanesulfonylamino-phenyl)-7-methoxy-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl}-methanesulfonamide
- 42 2-Chloro-6,6-bis-(4-hydroxy-phenyl)-3-methyl-4,6-dihydro-3H-pyrrolo[2,3-d]imidazol-5-one
- 43 Acetic acid 4-[6-(4-acetoxy-phenyl)-2-chloro-3-methyl-5-oxo-3,4,5,6-tetrahydro-pyrrolo[2,3-d]imidazol-6-yl]-phenyl ester
- 44 6,6-Bis-(4-amino-phenyl)-2-chloro-3-methyl-4,6-dihydro-3H-pyrrolo[2,3-d]imidazol-5-one
- 45 2-Chloro-6,6-bis-(4-dimethylamino-phenyl)-3-methyl-4,6-dihydro-3H-pyrrolo[2,3-d]imidazol-5-one
- 46 N-{4-[6-(4-Acetylamino-phenyl)-2-chloro-3-methyl-5-oxo-3,4,5,6-tetrahydro-pyrrolo[2,3-d]imidazol-6-yl]-phenyl}-acetamide
- 47 N-{4-[2-Chloro-6-(4-methanesulfonylamino-phenyl)-3-methyl-5-oxo-3,4,5,6-tetrahydro-pyrrolo[2,3-d]imidazol-6-yl]-phenyl}-methanesulfonamide
- 48 4,4-Bis-(4-hydroxy-phenyl)-1-methyl-4,6-dihydro-1H-pyrrolo[2,3-c]pyrazol-5-one
- 49 Acetic acid 4-[4-(4-acetoxy-phenyl)-1-methyl-5-oxo-1,4,5,6-tetrahydro-pyrrolo[2,3-c]pyrazol-4-yl]-phenyl ester
- 50 4,4-Bis-(4-amino-phenyl)-1-methyl-4,6-dihydro-1H-pyrrolo[2,3-c]pyrazol-5-one
- 51 N-{4-[4-(4-Methanesulfonylamino-phenyl)-1-methyl-5-oxo-1,4,5,6-tetrahydro-pyrrolo[2,3-c]pyrazol-4-yl]-phenyl}-methanesulfonamide
- 52 4,4-Bis-(4-dimethylamino-phenyl)-1-methyl-4,6-dihydro-1H-pyrrolo[2,3-c]pyrazol-5-one
- 53 N-{4-[4-(4-Acetylamino-phenyl)-1-methyl-5-oxo-1,4,5,6-tetrahydro-pyrrolo[2,3-c]pyrazol-4-yl]-phenyl}-acetamide

- 4,4-Bis-(4-hydroxy-phenyl)-2-methyl-2,6-dihydro-4H-pyrrolo[2,3-c]pyrazol-5-one
- 55 Acetic acid 4-[4-(4-acetoxy-phenyl)-2-methyl-5-oxo-2,4,5,6-tetrahydro-pyrrolo[2,3-c]pyrazol-4-yl]-phenyl ester
- 56 4,4-Bis-(4-amino-phenyl)-2-methyl-2,6-dihydro-4H-pyrrolo[2,3-c]pyrazol-5-one
- 57 4,4-Bis-(4-dimethylamino-phenyl)-2-methyl-2,6-dihydro-4H-pyrrolo[2,3-c]pyrazol-5-one
- 58 N-{4-[4-(4-Acetylamino-phenyl)-2-methyl-5-oxo-2,4,5,6-tetrahydro-pyrrolo[2,3-c]pyrazol-4-yl]-phenyl}-acetamide
- 59 N-{4-[4-(4-Methanesulfonylamino-phenyl)-2-methyl-5-oxo-2,4,5,6-tetrahydro-pyrrolo[2,3-c]pyrazol-4-yl]-phenyl}-methanesulfonamide
- 60 4,4-Bis-(4-hydroxy-phenyl)-4,6-dihydro-thieno[2,3-b]pyrrol-5-one
- 61 Acetic acid 4-[4-(4-acetoxy-phenyl)-5-oxo-5,6-dihydro-4H-thieno[2,3-b]pyrrol-4-yl]-phenyl ester
- 62 4,4-Bis-(4-amino-phenyl)-4,6-dihydro-thieno[2,3-b]pyrrol-5-one
- 63 4,4-Bis-(4-dimethylamino-phenyl)-4,6-dihydro-thieno[2,3-b]pyrrol-5-one
- 64 N-{4-[4-(4-Acetylamino-phenyl)-5-oxo-5,6-dihydro-4H-thieno[2,3-b]pyrrol-4-yl]-phenyl}-acetamide
- 65 N-{4-[4-(4-Methanesulfonylamino-phenyl)-5-oxo-5,6-dihydro-4H-thieno[2,3-b]pyrrol-4-yl]-phenyl}-methanesulfonamide
- 66 2-Chloro-4,4-bis-(4-hydroxy-phenyl)-4,6-dihydro-thieno[2,3-b]pyrrol-5-one
- 67 Acetic acid 4-[4-(4-acetoxy-phenyl)-2-chloro-5-oxo-5,6-dihydro-4H-thieno[2,3-b]pyrrol-4-yl]-phenyl ester
- 68 4,4-Bis-(4-amino-phenyl)-2-chloro-4,6-dihydro-thieno[2,3-b]pyrrol-5-one
- 69 2-Chloro-4,4-bis-(4-dimethylamino-phenyl)-4,6-dihydro-thieno[2,3-b]pyrrol-5-one
- 70 N-{4-[4-(4-Acetylamino-phenyl)-2-chloro-5-oxo-5,6-dihydro-4H-thieno[2,3-b]pyrrol-4-yl]-phenyl}-acetamide
- 71 N-{4-[2-Chloro-4-(4-methanesulfonylamino-phenyl)-5-oxo-5,6-dihydro-4H-thieno[2,3-b]pyrrol-4-yl]-phenyl}-methanesulfonamide
- 72 4,4-Bis-(4-hydroxy-phenyl)-4,6-dihydro-furo[2,3-b]pyrrol-5-one

- 73 Acetic acid 4-[4-(4-acetoxy-phenyl)-5-oxo-5,6-dihydro-4H-furo[2,3-b]pyrrol-4-yl]-phenyl ester
- 74 4,4-Bis-(4-amino-phenyl)-4,6-dihydro-furo[2,3-b]pyrrol-5-one
- 75 4,4-Bis-(4-dimethylamino-phenyl)-4,6-dihydro-furo[2,3-b]pyrrol-5-one
- 76 N-{4-[4-(4-Acetylamino-phenyl)-5-oxo-5,6-dihydro-4H-furo[2,3-b]pyrrol-4-yl]-phenyl}-acetamide
- 77 N-{4-[4-(4-Methanesulfonylamino-phenyl)-5-oxo-5,6-dihydro-4H-furo[2,3-b]pyrrol-4-yl]-phenyl}-methanesulfonamide
- 78 2-Chloro-4,4-bis-(4-hydroxy-phenyl)-4,6-dihydro-furo[2,3-b]pyrrol-5-one
- 79 Acetic acid 4-[4-(4-acetoxy-phenyl)-2-chloro-5-oxo-5,6-dihydro-4H-furo[2,3-b]pyrrol-4-yl]-phenyl ester
- 80 4,4-Bis-(4-amino-phenyl)-2-chloro-4,6-dihydro-furo[2,3-b]pyrrol-5-one
- 81 2-Chloro-4,4-bis-(4-dimethylamino-phenyl)-4,6-dihydro-furo[2,3-b]pyrrol-5-one
- 82 N-{4-[4-(4-Acetylamino-phenyl)-2-chloro-5-oxo-5,6-dihydro-4H-furo[2,3-b]pyrrol-4-yl]-phenyl}-acetamide
- 83 N-{4-[2-Chloro-4-(4-methanesulfonylamino-phenyl)-5-oxo-5,6-dihydro-4H-furo[2,3-b]pyrrol-4-yl]-phenyl}-methanesulfonamide
- 84 3,3-Bis-(4-hydroxy-phenyl)-6-methyl-3,8-dihydro-1H-1,8-diaza-as-indacen-2-one
- 85 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-methyl-2-oxo-1,2,3,8-tetrahydro-1,8-diaza-as-indacen-3-yl]-phenyl ester
- 86 3,3-Bis-(4-amino-phenyl)-6-methyl-3,8-dihydro-1H-1,8-diaza-as-indacen-2-one
- 87 3,3-Bis-(4-dimethylamino-phenyl)-6-methyl-3,8-dihydro-1H-1,8-diaza-as-indacen-2-one
- 88 N-{4-[3-(4-Acetylamino-phenyl)-6-methyl-2-oxo-1,2,3,8-tetrahydro-1,8-diaza-as-indacen-3-yl]-phenyl}-acetamide
- 89 N-{4-[3-(4-Methanesulfonylamino-phenyl)-6-methyl-2-oxo-1,2,3,8-tetrahydro-1,8-diaza-as-indacen-3-yl]-phenyl}-methanesulfonamide
- 90 3,3-Bis-(4-hydroxy-phenyl)-1,3-dihydro-benzo[g]indol-2-one
- 91 Acetic acid 4-[3-(4-acetoxy-phenyl)-2-oxo-2,3-dihydro-1H-benzo[g]indol-3-yl]-phenyl ester
- 92 3,3-Bis-(4-amino-phenyl)-1,3-dihydro-benzo[g]indol-2-one

- 93 3,3-Bis-(4-dimethylamino-phenyl)-1,3-dihydro-benzo[g]indol-2-one
- 94 N-{4-[3-(4-Acetylamino-phenyl)-2-oxo-2,3-dihydro-1H-benzo[g]indol-3-yl]-phenyl}-acetamide
- 95 N-{4-[3-(4-Methanesulfonylamino-phenyl)-2-oxo-2,3-dihydro-1H-benzo[g]indol-3-yl]-phenyl}-methanesulfonamide
- 96 1-Amino-6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one
- 97 Acetic acid 4-[3-(4-acetoxy-phenyl)-1-amino-6-chloro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester
- 98 N-{4-[3-(4-Acetylamino-phenyl)-1-amino-6-chloro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl}-acetamide
- 99 N-{4-[1-Amino-6-chloro-3-(4-methanesulfonylamino-phenyl)-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl}-methanesulfonamide
- 100 Acetic acid 4-[3-(4-acetoxy-phenyl)-1-acetylamino-6-chloro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester
- 101 N-[3,3-Bis-(4-amino-phenyl)-6-chloro-7-methyl-2-oxo-2,3-dihydro-indol-1-yl]-acetamide
- N-[6-Chloro-3,3-bis-(4-dimethylamino-phenyl)-7-methyl-2-oxo-2,3-dihydro-indol-1-yl]-acetamide
- 103 N-[3,3-Bis-(4-acetylamino-phenyl)-6-chloro-7-methyl-2-oxo-2,3-dihydro-indol-1-yl]-acetamide
- 104 N-[6-Chloro-3,3-bis-(4-methanesulfonylamino-phenyl)-7-methyl-2-oxo-2,3-dihydro-indol-1-yl]-acetamide
- 105 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indole-2-thione
- 106 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-7-methyl-2-thioxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester
- 107 3,3-Bis-(4-amino-phenyl)-6-chloro-7-methyl-1,3-dihydro-indole-2-thione
- 108 6-Chloro-3,3-bis-(4-dimethylamino-phenyl)-7-methyl-1,3-dihydro-indole-2-thione
- 109 N-{4-[3-(4-Acetylamino-phenyl)-6-chloro-7-methyl-2-thioxo-2,3-dihydro-1H-indol-3-yl]-phenyl}-acetamide

110 Methanesulfonic acid 4-[6-chloro-3-(4-methanesulfonyloxy-phenyl)-7-methyl-2-thioxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester

- 111 Acetic acid 4-[4-(4-acetoxy-phenyl)-2-chloro-5-thioxo-5,6-dihydro-4H-thieno[2,3-b]pyrrol-4-yl]-phenyl ester
- 112 Acetic acid 4-[4-(4-acetoxy-phenyl)-2-chloro-5-thioxo-5,6-dihydro-4H-furo[2,3-b]pyrrol-4-vl]-phenyl ester
- 113 6,6-Bis-(4-amino-phenyl)-2-chloro-3-methyl-4,6-dihydro-thieno[3,2-b]pyrrole-5-thione
- 114 2-Chloro-6,6-bis-(4-dimethylamino-phenyl)-3-methyl-4,6-dihydro-3H-pyrrolo[2,3-dlimidazole-5-thione
- 115 N-{4-[6-(4-Acetylamino-phenyl)-3-chloro-5-thioxo-1,4,5,6-tetrahydro-pyrrolo[3,2-c]pyrazol-6-yl]-phenyl}-acetamide
- 116 Methanesulfonic acid 4-[2-chloro-4-(4-methanesulfonyloxy-phenyl)-5-thioxo-5,6-dihydro-4H-furo[2,3-b]pyrrol-4-yl]-phenyl ester
- 117 6-Chloro-7-cyclopropyl-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 118 6-Chloro-7-cyclopropyl-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one
- 119 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-7-trifluoromethyl-1,3-dihydro-indol-2-one
- 120 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-7-trifluoromethyl-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one
- 121 6-Chloro-7-cyclopropoxy-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 122 6-Chloro-7-cyclopropoxy-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one
- 123 6-(4-Fluoro-phenoxy)-3,3-bis-(4-hydroxy-phenyl)-7-trifluoromethyl-1,3-dihydro-indol-2-one
- 124 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-7-cyclopropyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester
- 125 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-7-cyclopropyl-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl]-phenyl ester
- 126 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-2-oxo-7-trifluoromethyl-2,3-dihydro-1H-indol-3-yl]-phenyl ester

127 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-2-oxo-7-trifluoromethyl-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl]-phenyl ester

- 128 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-7-cyclopropoxy-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester
- 129 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-7-cyclopropoxy-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl]-phenyl ester
- 130 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-(4-fluoro-phenoxy)-2-oxo-7-trifluoromethyl-2,3-dihydro-1H-indol-3-yl]-phenyl ester
- 131 Dimethylamino-acetic acid 4-{6-chloro-7-cyclopropyl-3-[4-(2-dimethylamino-acetoxy)-phenyl]-2-oxo-2,3-dihydro-1H-indol-3-yl}-phenyl ester
- 132 Dimethylamino-acetic acid 4-{6-chloro-7-cyclopropyl-3-[4-(2-dimethylamino-acetoxy)-phenyl]-2-oxo-2,3-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl}-phenyl ester
- 133 Dimethylamino-acetic acid 4-{6-chloro-3-[4-(2-dimethylamino-acetoxy)-phenyl]-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl}-phenyl ester
- 134 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-7-trifluoromethoxy-1,3-dihydro-indol-2-one
- 135 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-2-oxo-7-trifluoromethoxy-2,3-dihydro-1H-indol-3-yl]-phenyl ester
- 136 Dimethylamino-acetic acid 4-{6-chloro-3-[4-(2-dimethylamino-acetoxy)-phenyl]-2-oxo-7-trifluoromethoxy-2,3-dihydro-1H-indol-3-yl}-phenyl ester
- 137 6-Chloro-4-fluoro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one
- 138 3-Chloro-7,7-bis-(4-hydroxy-phenyl)-4-methyl-5,7-dihydro-pyrrolo[3,2-c]pyridazin-6-one
- 139 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-4-fluoro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester
- 140 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-4,7-dimethyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester
- 141 Acetic acid 4-[7-(4-acetoxy-phenyl)-3-chloro-4-methyl-6-oxo-6,7-dihydro-5H-pyrrolo[3,2-c]pyridazin-7-yl]-phenyl ester
- 6-Chloro-4,5-difluoro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one

- 143 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-4,5-difluoro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester
- 144 3,3-Bis-(4-hydroxy-phenyl)-3,6,7,8-tetrahydro-1H-1-aza-as-indacen-2-one
- 145 3,3-Bis-(4-hydroxy-phenyl)-1,3,6,7,8,9-hexahydro-benzo[g]indol-2-one
- 146 3,3-Bis-(4-hydroxy-phenyl)-7-trifluoromethyl-1,3-dihydro-indol-2-one
- 147 7-Chloro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 148 3,3-Bis-(4-hydroxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-7-carbonitrile
- 149 7-Ethyl-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 150 3,3-Bis-(4-hydroxy-phenyl)-7-morpholin-4-yl-1,3-dihydro-indol-2-one
- 151 3,3-Bis-(4-hydroxy-phenyl)-7-isopropyl-1,3-dihydro-indol-2-one
- 152 7-tert-Butyl-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 153 3,3-Bis-(4-hydroxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-7-carboxylic acid dimethylamide
- 154 3,3-Bis-(4-hydroxy-phenyl)-7-(4-methyl-piperazine-1-carbonyl)-1,3-dihydro-indol-2-one
- 155 3,3-Bis-(4-hydroxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid
- 156 3,3-Bis-(4-hydroxy-phenyl)-2-oxo-2,3-dihydro-1H-indole-5-carboxylic acid dimethylamide
- 157 3,3-Bis-(4-hydroxy-phenyl)-5-(morpholine-4-carbonyl)-1,3-dihydro-indol-2-one
- 158 3,3-Bis-(4-hydroxy-phenyl)-4-methoxy-1,3-dihydro-indol-2-one
- 159 3.3-Bis-(4-hydroxy-phenyl)-6-methoxy-1,3-dihydro-indol-2-one
- 160 3,3-Bis-(4-hydroxy-phenyl)-5-(4-methyl-piperazine-1-carbonyl)-1,3-dihydro-indol-2-one
- 161 6-Chloro-3,3-bis-(4-mercapto-phenyl)-7-methyl-1,3-dihydro-indol-2-one
- 162 N-{4-[3-(4-Acetylamino-phenyl)-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl}-acetamide
- 163 3,3-Bis-(4-hydroxy-phenyl)-7-(3-methoxy-prop-1-ynyl)-1,3-dihydro-indol-2-one
- 164 3,3-Bis-(4-hydroxy-phenyl)-7-pyridin-3-yl-1,3-dihydro-indol-2-one
- 165 7-Bromo-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 166 6-Chloro-3,3-bis-(4-methanesulfonyl-phenyl)-7-methyl-1,3-dihydro-indol-2-one
- 167 6.6-Bis-(4-hydroxy-phenyl)-4,6-dihydro-pyrrolo[3,2-d]thiazol-5-one
- 168 6,6-Bis-(4-hydroxy-phenyl)-2-methyl-4,6-dihydro-pyrrolo[3,2-d]thiazol-5-one
- 169 6,6-Bis-(4-hydroxy-phenyl)-2-isopropyl-4,6-dihydro-pyrrolo[3,2-d]thiazol-5-one

- 2-Chloro-6,6-bis-(4-hydroxy-phenyl)-4,6-dihydro-pyrrolo[3,2-d]thiazol-5-one
- 171 4,4-Bis-(4-hydroxy-phenyl)-4,6-dihydro-pyrrolo[3,2-d]isothiazol-5-one
- 172 3,3-Bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-pyrrolo[2,3-c]pyridin-2-one
- 173 3,3-Bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-pyrrolo[3,2-b]pyridin-2-one
- 174 3,3-Bis-(4-fluoro-phenyl)-7-methyl-1,3-dihydro-pyrrolo[3,2-b]pyridin-2-one
- 175 3,3-Bis-(4-fluoro-phenyl)-7-methyl-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one
- 176 3,3-Bis-(4-fluoro-phenyl)-7-isopropyl-1,3-dihydro-pyrrolo[3,2-c]pyridin-2-one
- 3,3-Bis-(4-hydroxy-phenyl)-3,6,7,8-tetrahydro-1H-1,5-diaza-as-indacen-2-one
- 178 3,3-Bis-(4-hydroxy-phenyl)-3,6,7,8-tetrahydro-1H-1,4-diaza-as-indacen-2-one
- 179 3,3-Bis-(4-hydroxy-phenyl)-1,3,6,7,8,9-hexahydro-pyrrolo[3,2-c]quinolin-2-one
- 180 3,3-Bis-(4-hydroxy-phenyl)-1,3,6,7,8,9-hexahydro-pyrrolo[3,2-c]isoquinolin-2-one
- 181 5-Fluoro-3,3-bis-(4-hydroxy-phenyl)-3,6,7,8-tetrahydro-1H-1-aza-as-indacen-2-one
- 182 7-Ethyl-5-fluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 183 3,3-Bis-(4-hydroxy-phenyl)-1,3,6,8-tetrahydro-7-oxa-1-aza-as-indacen-2-one
- 184 3,3-Bis-(4-hydroxy-phenyl)-1,3,7,8-tetrahydro-6-oxa-1-aza-as-indacen-2-one
- 185 3,3-Bis-(4-hydroxy-phenyl)-1,6,7,9-tetrahydro-3H-8-oxa-1-aza-cyclopenta[a]naphthalen-2-one
- 186 3,3-Bis-(4-hydroxy-phenyl)-1,7,8,9-tetrahydro-3H-pyrano[2,3-g]indol-2-one
- 187 3,3-Bis-(4-hydroxy-phenyl)-7-methyl-3,6,7,8-tetrahydro-1H-1,7-diaza-as-indacen-2-one
- 188 3,3-Bis-(4-hydroxy-phenyl)-7-methyl-1,3,7,8-tetrahydro-1,7-diaza-as-indacene-2,6-dione
- 189 3,3-Bis-(4-hydroxy-phenyl)-7,8,8-trimethyl-1,3,7,8-tetrahydro-1,7-diaza-as-indacene-2,6-dione
- 190 3,3-Bis-(4-hydroxy-phenyl)-5-iodo-1,3-dihydro-indol-2-one
- 191 5-Amino-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 192 5-Amino-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one
- 193 6-Bromo-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one
- 7-Fluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 195 3,3-Bis-(4-hydroxy-phenyl)-7-methoxy-1,3-dihydro-indol-2-one
- 196 4.7-Dichloro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one

- 197 6-Chloro-3,3-bis-(4-hydroxy-phenyl)-1,7-dimethyl-1,3-dihydro-indol-2-one
- 198 6-Chloro-3,3-bis-(4-fluoro-phenyl)-7-methyl-1,3-dihydro-indol-2-one
- 199 3,3-Bis-(4-hydroxy-phenyl)-7-(morpholine-4-carbonyl)-1,3-dihydro-indol-2-one
- 200 3,3-Bis-(4-hydroxy-phenyl)-1,3-dihydro-pyrrolo[2,3-d]pyridin-2-one
- 201 N-{4-[6-Chloro-3-(4-methanesulfonylamino-phenyl)-7-methyl-2-oxo-2,3-dihydro-1H-indol-
- 3-yl]-phenyl}-methanesulfonamide
- 202 3,3-Bis-(4-hydroxy-phenyl)-4,7-dimethyl-1,3-dihydro-indol-2-one
- 203 3,3-Bis-(4-hydroxy-phenyl)-7-iodo-1,3-dihydro-indol-2-one
- 204 3,3-Bis-(4-hydroxy-phenyl)-7-pyridin-4-yl-1,3-dihydro-indol-2-one
- 205 Acetic acid 4-[3-(4-acetoxy-phenyl)-6-chloro-7-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester
- 206 3,3-Bis-(4-hydroxy-phenyl)-5-phenyl-1,3-dihydro-indol-2-one
- 207 3,3-Bis-(4-hydroxy-phenyl)-7-thiophen-2-yl-1,3-dihydro-indol-2-one
- 208 3,3-Bis-(4-hydroxy-phenyl)-5-pyridin-4-yl-1,3-dihydro-indol-2-one
- 209 3,3-Bis-(4-hydroxy-phenyl)-5-thiophen-2-yl-1,3-dihydro-indol-2-one
- 210 5,7-Difluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 211 6-Fluoro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one
- 212 3,3-Bis-(4-hydroxy-phenyl)-6-methoxy-7-methyl-1,3-dihydro-indol-2-one
- 213 6,7-Difluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 214 6-Chloro-7-fluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 215 5-Fluoro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one
- 216 3,3-Bis-(4-hydroxy-phenyl)-5-methoxy-7-methyl-1,3-dihydro-indol-2-one
- 217 3,3-Bis-(4-hydroxy-phenyl)-1,3-dihydro-pyrrolo[2,3-b]pyridin-2-one
- 218 7-Chloro-3,3-bis-(4-hydroxy-phenyl)-4-methoxy-1,3-dihydro-indol-2-one
- 219 6-Fluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one
- 220 N-[3,3-Bis-(4-hydroxy-phenyl)-2-oxo-2,3-dihydro-indol-1-yl]-acetamide
- 221 5-[3,3-Bis-(4-hydroxy-phenyl)-7-methyl-2-oxo-2,3-dihydro-1H-indol-6-yloxy]-pentanoic acid methyl ester
- 222 5-[3,3-Bis-(4-hydroxy-phenyl)-7-methyl-2-oxo-2,3-dihydro-1H-indol-6-yloxy]-pentanoic acid

223 5-[3,3-Bis-(4-hydroxy-phenyl)-7-methyl-2-oxo-2,3-dihydro-1H-indol-5-yloxy]-pentanoic acid methyl ester

Docket No.: 20517/0205421-US0

5-[3,3-Bis-(4-hydroxy-phenyl)-7-methyl-2-oxo-2,3-dihydro-1H-indol-5-yloxy]-pentanoic acid
 7-Chloro-6-fluoro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one.

Claim 29 (Currently amended): The <u>methoduse</u> according to <u>any one of the preceding claimsclaim</u>
1, wherein the medicament further comprises one or more other chemotherapeutic agents.

Claim 30 (Canceled)

Claim 31 (Currently amended): A compound of the general formula (I)

$$\begin{array}{c|c}
X^{1} \\
\downarrow & \\
R^{3} \downarrow^{3} \downarrow^{4} \\
\downarrow & \\
R^{2} \downarrow^{2} \downarrow^{1} \\
\downarrow & \\
R^{1} & \\
R^{N}
\end{array}$$

$$(I)$$

as defined in any one of the claims 1-23 claim 1, with the proviso that the compound is not one selected from

3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-4,5-dimethyl-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-5,7-dimethyl-1,3-dihydro-indol-2-one;

5-bromo-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;

5-chloro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-5-methoxy-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-5-methyl-1,3-dihydro-indol-2-one;

6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;

acetic acid 4-[3-(4-acetoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester; and acetic acid 4-[3-(4-acetoxy-phenyl)-5-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester.

Claim 32 (Currently amended): A 3,3-Diphenyl-1,3-dihydro-indol-2-one type compound of the formula (II)

Docket No.: 20517/0205421-US0

as defined in any one of the claims 24 28 claim 24, with the proviso that the compound is not one selected from:

3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-4,5-dimethyl-1,3-dihydro-indol-2-one

3,3-bis-(4-hydroxy-phenyl)-5,7-dimethyl-1,3-dihydro-indol-2-one;

5-bromo-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;

5-chloro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-5-methoxy-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-5-methyl-1,3-dihydro-indol-2-one;

6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;

acetic acid 4-[3-(4-acetoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester; and acetic acid 4-[3-(4-acetoxy-phenyl)-5-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester.

Claim 33 (Currently amended): A pharmaceutical composition comprising a compound as defined in any one of the claimsclaim 1-28 and a pharmaceutically acceptable carrier.

Claim 34 (New): A 3,3-Diphenyl-1,3-dihydro-indol-2-one type compound of the formula (II)

$$R^3$$
 Z X^1 X^1 X^2 X^3 X^4 X^4

as defined in claim 25, with the proviso that the compound is not one selected from:

3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-4,5-dimethyl-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-5,7-dimethyl-1,3-dihydro-indol-2-one;

5-bromo-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;

5-chloro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-5-methoxy-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-5-methyl-1,3-dihydro-indol-2-one;

6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;

acetic acid 4-[3-(4-acetoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester; and acetic acid 4-[3-(4-acetoxy-phenyl)-5-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester.

Claim 35 (New): A 3,3-Diphenyl-1,3-dihydro-indol-2-one type compound of the formula (II)

$$\begin{array}{c|c}
X^1 \\
X^2 \\
R^2 \\
R^1 \\
H
\end{array}$$
(II)

as defined in claim 26, with the proviso that the compound is not one selected from:

3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-4,5-dimethyl-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-5,7-dimethyl-1,3-dihydro-indol-2-one;

5-bromo-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;

5-chloro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;


3,3-bis-(4-hydroxy-phenyl)-5-methoxy-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-5-methyl-1,3-dihydro-indol-2-one;

6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;

acetic acid 4-[3-(4-acetoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester; and acetic acid 4-[3-(4-acetoxy-phenyl)-5-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester.

Claim 36 (New): A 3,3-Diphenyl-1,3-dihydro-indol-2-one type compound of the formula (II)



as defined in claim 27, with the proviso that the compound is not one selected from:

3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,

3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-4,5-dimethyl-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-5,7-dimethyl-1,3-dihydro-indol-2-one;

5-bromo-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;

5-chloro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-5-methoxy-1,3-dihydro-indol-2-one;

3,3-bis-(4-hydroxy-phenyl)-5-methyl-1,3-dihydro-indol-2-one;

6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;

acetic acid 4-[3-(4-acetoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester; and acetic acid 4-[3-(4-acetoxy-phenyl)-5-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester.

Claim 37 (New): A 3,3-Diphenyl-1,3-dihydro-indol-2-one type compound of the formula (II)

Docket No.: 20517/0205421-US0

$$R^3$$
 Z X^2

as defined in claim 28, with the proviso that the compound is not one selected from:

- 3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one,
- 3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;

(II)

- 3,3-bis-(4-hydroxy-phenyl)-4,5-dimethyl-1,3-dihydro-indol-2-one;
- 3,3-bis-(4-hydroxy-phenyl)-5,7-dimethyl-1,3-dihydro-indol-2-one;
- 5-bromo-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;
- 5-chloro-3,3-bis-(4-hydroxy-phenyl)-1,3-dihydro-indol-2-one;
- 3,3-bis-(4-hydroxy-phenyl)-5-methoxy-1,3-dihydro-indol-2-one;
- 3,3-bis-(4-hydroxy-phenyl)-5-methyl-1,3-dihydro-indol-2-one;
- 6-chloro-3,3-bis-(4-hydroxy-phenyl)-7-methyl-1,3-dihydro-indol-2-one;

acetic acid 4-[3-(4-acetoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester; and acetic acid 4-[3-(4-acetoxy-phenyl)-5-methyl-2-oxo-2,3-dihydro-1H-indol-3-yl]-phenyl ester.